Autologous platelets as a source of proteins for healing and tissue regeneration

Summary

Platelets are known for their role in haemostasis where they help prevent blood loss at sites of vascular injury. To do this, they adhere, aggregate and form a procoagulant surface leading to thrombin generation and fibrin formation. Platelets also release substances that promote tissue repair and influence the reactivity of vascular and other blood cells in angiogenesis and inflammation. They contain storage pools of growth factors including PDGF, TGF-β and VEGF as well as cytokines including proteins such as PF4 and CD40L. Chemokines and newly synthesised active metabolites are also released. The fact that platelets secrete growth factors and active metabolites means that their applied use can have a positive influence in clinical situations requiring rapid healing and tissue regeneration. Their administration in fibrin clot or fibrin glue provides an adhesive support that can confine secretion to a chosen site. Additionally, the presentation of growth factors attached to platelets and/or fibrin may result in enhanced activity over recombinant proteins. Dental implant surgery with guided bone regeneration is one situation where an autologous platelet-rich clot clearly accelerates ossification after tooth extraction and/or around titanium implants. The end result is both marked reductions in the time required for implant stabilisation and an improved success rate. Orthopaedic surgery, muscle and/or tendon repair, reversal of skin ulcers, hole repair in eye surgery and cosmetic surgery are other situations where autologous platelets accelerate healing. Our aim is to review these advances and discuss the ways in which platelets may provide such unexpected beneficial therapeutic effects.

Keywords

Platelets - growth factors - cytokines - healing - dental implant surgery - tissue repair

• References

• 1 George JN. Platelets. Lancet 2000; 355: 1531-9.
• 2 Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-66.
• 3 Hato T, Ginsberg MH, Shattil SJ. IntegrinαIIbβ3. In Platelets. ed: Michelson AD. Elsevier Science; San Diego: 2002: 105-16.
• 4 Abrams CS, Brass LF. Platelet signal transduction. In Hemostasis and Thrombosis. Basic Principles and Clinical Practice. eds: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. Lippincott, Williams & Wilkins, Philadelphia; 2001: 541-59.
• 5 Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 2002; 22: 364-73.
• 6 Lansdown AB. Calcium: a potential central regulator in wound healing in the skin. Wound Repair Regen 2002; 10: 271-85.
• 7 Rendu F, Brohard-Bohn B. The platelet release reaction: granules’ constituents, secretion and function. Platelets 2001; 12: 261-73.
• 8 Reed GL. Platelet secretion. In Platelets. ed: Michelson AD. Elsevier Science; San Diego: 2002: 181-95.
• 9 Zhou YQ, Levesque JP, Hatzfeld A. et al.. Fibrinogen potentiates the effect of interleukin-3 on early human hematopoietic progenitors. Blood 1993; 82: 800-6.
• 10 Lariviere B, Rouleau M, Picard S. et al.. Human plasma fibronectin potentiates the mitogenic activity of platelet-derived growth factor and complements its wound healing effects. Wound Repair Regen 2003; 11: 79-89.
• 11 Minor KH, Peterson CB. Plasminogen activator inhibitor type I promotes the self-association of vitronectin into complexes exhibiting altered incorporation into the extracellular matrix. J Biol Chem 2002; 277: 10337-45.
• 12 Kelm RJ, Swords NA, Orfeo T. et al.. Osteonectin in matrix remodelling. A plasminogenosteonectin-collagen complex. J Biol Chem 1994; 269: 30147-53.
• 13 Mosnier LO, Buijenhuis P, Marx PF. et al.. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101: 4844-6.
• 14 Folkman J, Browder T, Palmblad J. Angiogenesis research: Guidelines for translation to clinical application. Thromb Haemost 2001; 86: 23-33.
• 15 Ostman A, Heldin C-H. Involvement of platelet-derived growth factor in disease: Development of specific antagonists. Adv Cancer Res 2001; 80: 1-37.
• 16 Yu Y, Sweeney M, Zhang S. et al.. PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. Am J Cell Physiol 2003; 284: C316-30.
• 17 Romanashkova JA, Makarov SS. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401: 86-90.
• 18 Pintucci G, Froum S, Pinnell J. et al.. Trophic effects of platelets on endothelial cells are mediated by platelet-associated fibroblast growth factor (FGF-2) and vascular endothelial growth factor (VEGF). Thromb Haemost 2002; 88: 834-42.
• 19 Weltermann A, Wolzt M, Petersmann K. et al.. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 1757-60.
• 20 Galvin KM, Donovan MJ, Lynch CA. et al.. A role for Smad6 in development and homeostasis of the cardiovascular system. Nature Gen 2000; 24: 171-4.
• 21 Yee JA, Yan L, Dominguez JC. et al.. Plasminogen-dependent activation of latent transforming growth factor β (TGF-β) by growing cultures of osteoblast-like cells. J Cell Physiol 1993; 157: 528-34.
• 22 Taylor VL, Spencer EM. Characterization of insulin-like growth factor-binding protein-3 binding to a novel receptor on human platelet membranes. J Endocrinol 2001; 168: 307-13.
• 23 Hagedorn M, Zilberberg L, Wilting J. et al.. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Cancer Res 2002; 62: 6884-90.
• 24 Sulpice E, Bryckaert M, Lacour J. et al.. Platelet factor 4 inhibits EGF2-induced endothelial cell proliferation via the extracellular signal-related kinase pathway but not by the phosphatidylinositol 3-kinase pathway. Blood 2002; 100: 3087-94.
• 25 Krijgsveld J, Zaat SA, Meeldijk J. et al.. Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J Biol Chem 2000; 265: 20374-81.
• 26 Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun 2002; 70: 6515-7.
• 27 Schober A, Manka D, von Hundelshausen P. et al.. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106: 1523-9.
• 28 Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003; 10: 335-50.
• 29 Henn V, Slupsky JR, Gräfe M. et al.. CD-40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
• 30 Anand SX, Viles-Gonzalez JF, Badimon JJ. et al.. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003; 90: 377-84.
• 31 André P, Nannizzi-Alaimo L, Prasad SK. et al.. Platelet-derived CD40L. The switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896-9.
• 32 Carmeliet P, Mackman N, Moons L. et al.. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383: 73-5.
• 33 Balasubramanian V, Grabowski E, Bini A. et al.. Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions. Blood 2002; 100: 2787-92.
• 34 Leon C, Alex M, Klocke A. et al.. Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood. 2003 (Epub ahead of print.)
• 35 Fan Z, Larson PJ, Bognacki J. et al.. Tissue factor regulates plasminogen binding and activation. Blood 1998; 91: 1987-98.
• 36 Sato Y, Asada Y, Marutska K. et al.. Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 1996; 75: 389-92.
• 37 Nurden P, Poujol C, Durrieu-Jais C. et al.. Labeling of the internal pool of GPIIb-IIIa in platelets of patients receiving c7E3 Fab fragments (abciximab, ReoPro): Flow and endocytic mechanisms contribute to the transport. Blood 1999; 93: 1622-33.
• 38 Nurden P, Poujol C, Winckler J. et al.. Immunolocalization of P2Y₁ and TPα receptors in platelets showed a major pool associated with the membranes of α-granules and the open canalicular system. Blood 2003; 101: 1400-8.
• 39 McEver RP. P-selectin and PSGL-1: Exploiting connections between inflammation and venous thrombosis. Thromb Haemost 2002; 87: 364-5.
• 40 Cheng Y, Austin SC, Rocca B. et al.. Role of prostacyclin in the cardiovascular response to thromboxane A₂ . Science 2002; 296: 474-5.
• 41 Zhang Q, Peyruchaud O, French KJ. et al.. Sphingosine 1-phosphate stimulates fibronectin matrix assembly through a Rho-dependent signal pathway. Blood 1999; 93: 2984-90.
• 42 Garcia JG, Liu F, Verin AD. et al.. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 2001; 108: 689-701.
• 43 Takeya H, Gabazza EC, Aoki S. et al.. Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells. Blood 2003; 102: 1693-700.
• 44 Weyrich AS, Prescott SM, Zimmerman GA. Platelets, endothelial cells, inflammatory chemokines, and restenosis Complex signaling in the vascular play book. Circulation 2002; 106: 1433-5.
• 45 Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler. Thromb Vasc Biol 2002; 22: 1381-9.
• 46 Bachli EB, Pech CM, Johnson KM. et al.. Factor Xa and thrombin, but not factor VIIa, ellicit specific cellular responses in dermal fibroblasts. J Thromb Haemost 2003; 01: 1935-44.
• 47 Whitman DH, Berry RL, Green DM. Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J Oral Maxillofac Surg 1997; 55: 1294-9.
• 48 Marx RE, Carson ER, Eichstaedt RN. et al.. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85: 638-46.
• 49 Sänchez AR, Sheridan PJ, Kupp LI. Is platelet-rich plasma the perfect enhancement factor? A current review. Int J Oral Maxillofac Implants 2003; 18: 93-103.
• 50 Zimmermann R, Jakubietz R, Strasser E. et al.. Different preparation methods to obtain platelet components as a source of growth factors for local application. Transfusion 2001; 41: 1217-24.
• 51 Landesberg R, Moses M, Karpatkin M. Risk of using platelet-rich plasma gel. J Oral Maxillofac Surg 1998; 56: 1116-7.
• 52 Anitua E. Plasma rich in growth factors: Preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants 1999; 14: 529-35.
• 53 Weibrich G, Kleis WKG, Hafner G. et al.. Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Carnio-Maxilofac Surg 2002; 30: 97-102.
• 54 Lind M. Growth factor stimulation of bone healing. Effects on osteoblasts, osteomies, and implant fixation. Acta Orthop Scand Suppl 1998; 283: 3-27.
• 55 Cochran DL, Schenk R, Buser D. et al.. Recombinant human bone morphogenetic protein-2 stimulation of bone formation around endosseous dental implants. J Periodontol 1999; 70: 139-50.
• 56 Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000; 289: 1501-4.
• 57 Harada S-I, Rodan GA. Control of osteoblast function and regultaion of bone mass. Nature 2003; 423: 349-55.
• 58 Fauchaux C, Bareille R, Amadée J. et al.. Effect of 1,25(OH)₂D₃ on bone morphogenetic protein-3 mRNA expression. J Cell Biochem 1999; 73: 11-19.
• 59 Centrella M, Horowitz M, Wozney J. et al.. Transforming growth factor β gene family members and bone. Endocrinol Rev 1994; 15: 27-39.
• 60 Slater M, Patava J, Kingham K. et al.. Involvement of platelets in stimulating osteogenic activity. J Orthop Res 1995; 13: 655-63.
• 61 Oprea WE, Karp JM, Hosseini MM. et al.. Effect of platelet releasate on bone cell migration and recruitment in vitro. J Craniofac Surg 2003; 14: 292-300.
• 62 Tischler M. Platelet rich plasma. The use of autologous growth factors to enhance bone and soft tissue grafts. NY State Dent J 2002; 68: 22-4.
• 63 De Obarrio JJ, Arauz-Dutari JI, Chamberlain TM. et al.. The use of autologous growth factors in periodontal surgical therapy: platelet gel biotechnology case-reports. Int J Periodontics Restorative Dent 2000; 20: 486-97.
• 64 Rodriguez A, Anastossov GE, Lee H. et al.. Maxillary sinus augmentation with deproteinated bovine bone and platelet rich plasma with simultaneous insertion of endosseous implants. J Oral Maxillofac Surg 2003; 61: 157-63.
• 65 Anitua E, Andia IOrtiz. BTI implant system: The first implant system with a bioactive surface. Maxillaris 2001; 39: 2-7.
• 66 Anitua E, Ardanza B, Paponneau A. et al.. Clots from platelet-rich plasma promote bone regeneration in so doing reducing the time needed for dental implants and favouring their osteointegration. Blood 2001; 11: 242a.
• 67 Rahal MD, Branemark PL, Osmond DG. Response of bone marrow to titanium implants: osseointegration and the establishment of a bone marrow-titanium interface in mice. Int J Oral Maxillofac Implants 1993; 08: 573-9.
• 68 Broberg M, Eriksson C, Nygren H. GPIIb/IIIa is the main receptor for initial platelet adhesion to glass and titanium surfaces in contact with whole blood. J Lab Clin Med 2002; 139: 163-72.
• 69 Park JY, Gemmell CH, Davies JE. Platelet interactions with titanium: modulation of platelet activity by surface topography. Biomaterials 2001; 22: 2671-82.
• 70 Krause A, Cowles EA, Gronowicz G. Integrin-mediated signaling in osteoblasts on titanium implant materials. J Biomed Mater Res 2000; 52: 738-47.
• 71 Zechner W, Tangl S, Tepper G. et al.. Influence of platelet-rich plasma on osseous healing of dental implants: A histologic and histomorphometric study in minipigs. Int J Oral Maxillofac Implants 2003; 18: 15-22.
• 72 Stefani CM, Machado MA, Sallum EA. et al.. Platelet-derived growth factor/insulin-like growth factor-1 combination and bone regeneration around implants placed into extraction sockets: A histometric study in dogs. Implant Dent 2000; 09: 126-31.
• 73 Takai H, Kanematsu M, Yano K. et al.. Transforming growth factor-β stimulates the proliferation of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 1998; 273: 27091-6.
• 74 Kubota K, Sakikawa C, Katsuma M. et al.. Platelet-derived growth factor BB secreted from osteoclasts as an osteoblastogenesis inhibitory factor. J Bone Miner Res 2002; 17: 257-65.
• 75 Matsuo K, Owens JM, Tonko M. et al.. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nature Genetics 2000; 24: 184-7.
• 76 Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22: 549-53.
• 77 Gruber R, Karreth F, Fischer MB. et al.. Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. Bone 2002; 30: 726-32.
• 78 Feng X, Novack DV, Faccio R. et al.. A Glanzmann’s mutation in β3 integrin specifically impairs osteoclast function. J Clin Invest 2001; 107: 1137-44.
• 79 Takana T, Liang CT. Effect of platelet-derived growth factor on DNA synthesis and gene expression in bone marrow stromal cells derived from adult and old rats. J Cell Physiol 1995; 164: 367-75.
• 80 Yang D, Chen J, Jing Z. et al.. Platelet-derived growth factor (PDGF)-AA: a self-imposed cytokine in the proliferation of human fetal osteoblasts. Cytokine 2000; 12: 1271-4.
• 81 Joyce ME, Roberts AB, Sporn MB. et al.. Transforming growth factor-β and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol 1990; 110: 2195-207.
• 82 McCarthy TL, Casinghino S, Centrella M. et al.. Complex pattern of insulin-like growth factor binding protein expression in primary rat osteoblast enriched cultures: regulation by prostaglandin E2, growth hormones, and insulin-like growth factors. J Cell Physiol 1994; 160: 163-75.
• 83 Bhanot S, Alex JC. Current applications of platelet gels in facial plastic surgery. Facial Plast Surg 2002; 18: 27-33.
• 84 Valbonesi M, Giannini G, Migliori F. et al.. The role of autologous fibrin-platelet glue in plastic surgery: a preliminary report. Int J Artif Organs 2002; 25: 334-8.
• 85 Powell DM, Chang E, Farrior EH. Recovery from deep-plane rhytidectomy following unilateral wound treatment with autologous platelet gel: a pilot study. Arch Facial Plast Surg 2001; 03: 245-50.
• 86 Man D, Plosker H, Winland-Brown JE. The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery. Plast Reconstr Surg 2001; 107: 229-37.
• 87 Atri SS, Misra J, Bisht D. et al.. Use of homologous platelet factors in achieving total healing of recalcitrant skin ulcers. Surgery 1990; 108: 508-12.
• 88 Herouy Y, Mellios P, Bandemir E. et al.. Autologous platelet-derived wound healing factor promotes angiogenesis via αvβ3 integrin expression in chronic wounds. Int J Mol Med 2000; 06: 515-9.
• 89 Margolis DJ, Kantor J, Santanna J. et al.. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001; 24: 483-8.
• 90 Tarroni G, Tessarin C, De Silvestro L. et al.. Local therapy with platelet-derived growth factors for chronic diabetic ulcers in haemodialysis patients. G Ital Nefrol 2002; 19: 630-3.
• 91 Gilsanz F, Escalante F, Auray C. et al.. Treatment of leg ulcers in β-thalassemia inter-media: Use of platelet-derived wound healing factors from the patient’s own platelets. Br J Haematol 2001; 115: 710.
• 92 Lowery GL, Kulkarni S, Pennisi AE. Use of autologous growth factors in lumbar spinal fusion. Bone 1999; 25 (Suppl. 02) 478-508.
• 93 Fennis JP, Stoelinga PJ, Jansen JA. Mandibular reconstruction: a clinical and radiographic animal study on the use of autogenous scaffolds and platelet-rich plasma. Int J Oral Maxillofac Surg 2002; 31: 281-6.
• 94 Pâques M, Chastang C, Mathis A. et al.. Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicenter, double-masked, randomized trial. Platelets in Macular Hole Surgery Group. Ophthalmology 1999; 106: 932-8.
• 95 Gehring S, Hoerauf H, Laqua H. et al.. Preparation of autologous platelets for the ophthalmologic treatment of macular holes. Transfusion 1999; 39: 144-8.
• 96 Cullinane AB, O’Callaghan P, McDermott K. et al.. Effects of autologous platelet concentrate and serum on retinal wound healing in an animal model. Graefes Arch Clin Exp Ophthalmol 2002; 240: 35-41.
• 97 Zieren J, Castenholz E, Baumgart E. et al.. Effects of fibrin glue and growth factors released from platelets on abdominal hernia repair with a resorbable PGA mesh: Experimental study. J Surg Res 1999; 85: 267-72.
• 98 Sanchez M, Azofra J, Anitua E. et al.. Plasma rich in growth factors to treat an articular cartilage avulsion: a case report. Med Sci Sports Exerc 2003; 35: 1648-52.
• 99 Molloy T, Wang Y, Murrell G. The roles of growth factors in tendon and ligament healing. Sports Med 2003; 33: 381-94.
• 100 Sanchez M, Azofra J, Aizpurua B. et al.. Use of autologous plasma rich in growth factors in arthroscopic surgery. Cuader. Artroscopia 2003; 10: 12-9.
• 101 Fibbi G, D’Alession S, Pucci M. et al.. Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system. J Biol Chem 2002; 383: 127-36.
• 102 Lindemann S, Tolley ND, Dixon DA. et al.. Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis. J Cell Biol 2001; 154: 485-90.
• 103 Barry OP, Kazanietz MG, Pratico D. et al.. Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway. J Biol Chem 1999; 274: 7545-56.
• 104 Ma L, Elliott SN, Cirino G. et al.. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA 2001; 98: 6470-5.
• 105 Sasaki T, Hohenester E, Timpl R. Structure and function of collagen-derived endostatin inhibitors of angiogenesis. IUBMB Life 2002; 53: 77-84.
• 106 Carlson NE, Roach Jr RB. Platelet-rich plasma: clinical applications in dentistry. J Am Dent Assoc 2002; 133: 1383-6.
• 107 Tziafas D, Papadimitriou S. Role of exogenous TGF-β in induction of reparative dentinogenesis in vivo. Eur J Oral Sci 1998; 106: 192-6.
• 108 Yamaguchi Y, Yoshikawa K. Cutaneous wound healing: an update. J Dermatol 2001; 28: 521-34.
• 109 Schoppet M, Chavakis T, Al-Fakhri N. et al.. Molecular interactions and functional interference between vitronectin and transforming growth factor-β. Lab Invest 2002; 82: 37-46.
• 110 Tezono K, Sarker KP, Kikuchi H. et al.. Bioactivity of the vascular endothelial growth factor trapped in fibrin clots: production of IL-6 and IL-8 in monocytes by fibrin clots. Haemostasis 2001; 31: 71-9.
• 111 Sahni A, Altland OD, Francis CW. FGF-2 but not FGF-1 binds fibrin and supports prolonged endothélial cell growth. J Thromb Haemost 2003; 01: 1304-10.
• 112 Haack H, Hynes RO. Integrin receptors are required for cell survival and proliferation during development of the peripheral glial lineage. Dev Biol 2001; 233: 38-55.
• 113 Weber AA, Zucker TP, Schror K. Platelet surface membranes are highly mitogenic for coronary artery smooth muscle cells. A novel mechanism for sustained proliferation after vessel injury. Biochem Biophys Res Commun 1999; 259: 341-3.
• 114 Borges E, Jan Y, Ruoslahti E. O Plateletderived growth factor receptor β and vascular endothelial growth factor receptor 2 bind to the β3 integrin through its extracellular domain. J Biol Chem 2000; 275: 39867-73.
• 115 Lariviere B, Rouleau M, Picard S. et al.. Human plasma fibronectin potentiates the mitogenic activity of platelet-derived growth factor and complements its wound healing effects. Wound Repair Regen 2003; 11: 79-89.
• 116 Yee JA, Yan L, Dominguez JC. et al.. Plasminogen-dependent activation of latent transforming growth factor β (TGF β) by growing cultures of osteoblast-like cells. J Cell Physiol 1993; 157: 528-34.
• 117 Zhu Z, Lee CS, Tejeda KM. et al.. Gene transfer and expression of platelet-derived growth factors modulate periodontal cellular activity. J Dent Res 2001; 80: 892-7.